Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARP14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP14_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP14_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP14_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PARP14_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP14_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP14_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003434113 | Prostate | Tumor | response to interferon-gamma | 37/3246 | 141/18723 | 5.07e-03 | 2.46e-02 | 37 |
GO:007067011 | Prostate | Tumor | response to interleukin-4 | 13/3246 | 36/18723 | 5.47e-03 | 2.60e-02 | 13 |
GO:00028316 | Prostate | Tumor | regulation of response to biotic stimulus | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
GO:00713464 | Prostate | Tumor | cellular response to interferon-gamma | 31/3246 | 118/18723 | 9.53e-03 | 4.09e-02 | 31 |
GO:00603334 | Prostate | Tumor | interferon-gamma-mediated signaling pathway | 10/3246 | 27/18723 | 1.17e-02 | 4.79e-02 | 10 |
GO:004593628 | Skin | cSCC | negative regulation of phosphate metabolic process | 160/4864 | 441/18723 | 8.89e-07 | 1.63e-05 | 160 |
GO:001056328 | Skin | cSCC | negative regulation of phosphorus metabolic process | 160/4864 | 442/18723 | 1.04e-06 | 1.85e-05 | 160 |
GO:004232626 | Skin | cSCC | negative regulation of phosphorylation | 137/4864 | 385/18723 | 1.63e-05 | 1.99e-04 | 137 |
GO:000193326 | Skin | cSCC | negative regulation of protein phosphorylation | 123/4864 | 342/18723 | 2.48e-05 | 2.82e-04 | 123 |
GO:003434115 | Skin | cSCC | response to interferon-gamma | 57/4864 | 141/18723 | 1.20e-04 | 1.11e-03 | 57 |
GO:000283122 | Skin | cSCC | regulation of response to biotic stimulus | 112/4864 | 327/18723 | 5.00e-04 | 3.76e-03 | 112 |
GO:007134613 | Skin | cSCC | cellular response to interferon-gamma | 47/4864 | 118/18723 | 6.71e-04 | 4.79e-03 | 47 |
GO:00603337 | Skin | cSCC | interferon-gamma-mediated signaling pathway | 15/4864 | 27/18723 | 1.03e-03 | 6.94e-03 | 15 |
GO:00028326 | Skin | cSCC | negative regulation of response to biotic stimulus | 43/4864 | 108/18723 | 1.12e-03 | 7.36e-03 | 43 |
GO:00713536 | Skin | cSCC | cellular response to interleukin-4 | 17/4864 | 33/18723 | 1.50e-03 | 9.36e-03 | 17 |
GO:004508812 | Skin | cSCC | regulation of innate immune response | 75/4864 | 218/18723 | 3.40e-03 | 1.84e-02 | 75 |
GO:00507323 | Skin | cSCC | negative regulation of peptidyl-tyrosine phosphorylation | 25/4864 | 59/18723 | 4.46e-03 | 2.29e-02 | 25 |
GO:00706706 | Skin | cSCC | response to interleukin-4 | 17/4864 | 36/18723 | 4.85e-03 | 2.46e-02 | 17 |
GO:00607596 | Skin | cSCC | regulation of response to cytokine stimulus | 57/4864 | 162/18723 | 5.77e-03 | 2.85e-02 | 57 |
GO:00458246 | Skin | cSCC | negative regulation of innate immune response | 28/4864 | 71/18723 | 8.86e-03 | 4.07e-02 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP14 | SNV | Missense_Mutation | | c.2578C>G | p.Leu860Val | p.L860V | Q460N5 | protein_coding | tolerated(0.53) | benign(0.047) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2665N>A | p.Glu889Lys | p.E889K | Q460N5 | protein_coding | tolerated(0.14) | benign(0.037) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.2473N>A | p.Glu825Lys | p.E825K | Q460N5 | protein_coding | deleterious(0.02) | possibly_damaging(0.749) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | | c.4653N>T | p.Met1551Ile | p.M1551I | Q460N5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.142N>T | p.Pro48Ser | p.P48S | Q460N5 | protein_coding | tolerated(0.07) | possibly_damaging(0.609) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | novel | c.5212N>A | p.Val1738Met | p.V1738M | Q460N5 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2375G>C | p.Cys792Ser | p.C792S | Q460N5 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PARP14 | SNV | Missense_Mutation | | c.763N>C | p.Gly255Arg | p.G255R | Q460N5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PARP14 | SNV | Missense_Mutation | | c.4396G>C | p.Asp1466His | p.D1466H | Q460N5 | protein_coding | tolerated(0.13) | benign(0.048) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP14 | SNV | Missense_Mutation | | c.3835N>G | p.Gln1279Glu | p.Q1279E | Q460N5 | protein_coding | tolerated(1) | benign(0.372) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |